📰 Clinical Development News
Page 37 - Clinical Development News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Clinical Development. Real-time updates on events, politics, business and more.
February 19, 2024
Herefordshire and Worcestershire Health and Care NHS Trusts nursing programme has been shortlisted for the Nurse Education Provider of the Year.
February 18, 2024
Artax Biopharma, a clinical-stage biotech company focused on transforming the treatment of autoimmune diseases, has dosed the first patient in its phase 2a trial evaluating oral, small molecule, AX-158 for the treatment of psoriasis.
February 16, 2024
The Department of Paediatrics at the University of Oxford, has entered into an agreement with three Brazilian Universities, to contribute to the delivery of an undergraduate course in ‘Translational Science’, starting in 2024.The course, which will e
February 15, 2024
Company Provides 2024 Guidance Results from Continuing Operations for the fourth quarter and full year versus last year:Revenue: Q4 of $3.03 billion vs $2.93 billion; Full year of $12.16 billion vs...
February 15, 2024
MANNKIND ANNOUNCES ENROLLMENT GOAL COMPLETION OF INHALE-1 PEDIATRIC DIABETES TRIAL UTILIZING AFREZZA...
February 15, 2024
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024. Michelle will succeed Henry Adewoye, M.D., who is leaving Compugen to pursue other opportunities effective February 29, 2024, after 6 years with Compugen.
February 15, 2024
Reached enrollment goal of 305 patients living with Type 1 or Type 2 diabetesPrimary endpoint analysis expected in 4Q 2024Data dissemination and FDA submission expected in 2025
February 15, 2024
Dsm-firmenich, today (February 15) announces its exclusive partnership with Zerion Pharma A/S to unlock a new era in cannabinoid innovation that champions patient-centric formulations.
February 15, 2024
Artax Biopharma, a clinical-stage biotech company focused on transforming the treatment of autoimmune diseases, has dosed the first patient in its phase 2a trial evaluating oral, small molecule, AX-158 for the treatment of psoriasis.
February 15, 2024
Stella Vnook, a seasoned veteran in the pharmaceutical industry with extensive experience in senior leadership roles at Catalent, Merck, and Diverse Biotech, has been a prominent figure in the field, particularly in oncology, for over 25 years.